Edwards Announces Positive Data On Transfemoral Transcatheter Tricuspid Valve Replacement
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Edwards Lifesciences Corp. (EW) said that one-year results on patients treated in TRISCEND study of the company’s EVOQUE transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes.
:max_bytes(150000):strip_icc():format(jpeg)/Primary-Image-marcus-cd-rates-april-2023-7482142-12157d4201c44c4aafe6fe5394bc5fe5.jpg "Marcus CD Rates: April 2024")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-509472718-14b96437e99e4dd38831d4b74602dcf5.jpg "Retirement Annuities: Know the Pros and Cons")